Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $125.75, giving the company a market capitalization of 156.16B. It carries a P/E multiple of 19.75 and pays a dividend yield of 2.5%.
During the trading session on 2025-11-29, Gilead Sciences(GILD) shares reached a daily high of $127.80 and a low of $124.90. At a current price of $125.75, the stock is +0.7% higher than the low and still -1.6% under the high.
Trading activity shows a volume of 2.97M, compared to an average daily volume of 7.38M.
The stock's 52-week range extends from a low of $88.57 to a high of $128.70.
The stock's 52-week range extends from a low of $88.57 to a high of $128.70.
GILD News
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...
Wondering if Gilead Sciences is actually a bargain or overpriced right now? You are not alone, especially with so much chatter about the company's future outloo...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Gilead Sciences today and set a price target of $135.00. TipRanks Black Friday Sale Claim 60% off...
Analyst ratings
71%
of 31 ratingsMore GILD News
BMO Capital says Phase 1 data from three patients in Kelonia Therapeutics’ inMMyCAR study “look interesting,” with all patients reaching MRD negativity by month...